An Observational Follow-Up Study of Patients Previously Enrolled in ADR-001-01 Study Against Liver Cirrhosis
Latest Information Update: 22 Nov 2023
At a glance
- Drugs ADR-001 (Primary)
- Indications Liver cirrhosis
- Focus Adverse reactions
- Sponsors Rohto Pharmaceutical
- 14 Nov 2023 Status changed from recruiting to completed.
- 30 Mar 2023 Planned End Date changed from 30 Jun 2023 to 29 Feb 2024.
- 30 Mar 2023 Planned primary completion date changed from 31 Dec 2022 to 27 Oct 2023.